KDx Diagnostics Inc. is the developer of the Uro17™ bladder cancer test, which should be the most sensitive and specific urine test for bladder cancer detection when launched. Co-inventor and exclusive licensee of the underlying technology, KDx Diagnostics Inc. is finalizing the testing required for commercialization. Our proof of concept based on 600+ samples tested to date, and a key scientific publication accepted by a high-impact peer-reviewed journal and reports study showing 100% sensitivity and 96% specificity, proves that Uro17 urine test could potentially replace the current gold standard in bladder cancer diagnosis and monitoring, which currently requires an invasive procedure and expensive imaging technology. Contact us directly or via our distributors: Sweden, Norway, Finland, XBoxLab, https://www.xboxlab.se/ Denmark, LabLab, https://www.lablab.dk/ Switzerland, Labforce AG, https://www.labforce.ch/ Singapore, Weavegen, https://www.weavegen.com/ Italy, Medical Horizons,